

GEORGIA BOARD OF PHARMACY
2 MLK Jr. Drive, SE, 11th Floor, East Tower
Atlanta, GA 30334
May 8, 2024
9:00 a.m.

Board Members present:

Mr. Chuck Page, President
Mr. Cecil Cordle, Vice-President
Mr. Michael Azzolin
Mr. Jim Bracewell
Mr. Young Chang
Mr. Dean Stone

Board Staff present:

James Joiner, Executive Director
Dennis Troughton, Director, GDNA
Michael Karnbach, Deputy Director, GDNA
Eric Durham, Special Agent, GDNA
Justin Cotton, Assistant Attorney General

Visitors:

Katie Johnston, Revelation Pharmacy
Stephanie Kirkland, Elder Care
Heather Hughes, Publix
D. Scott Bass, GPhA
Will Marquess
Shea Ross-Smith, KP
Brandon Brooks, Publix
Brian Morris, Gwinnett Drugs

Becca Hallem, GHA
Jennifer Duckett, Walgreens
Melissa Reybold, GPhA
Jonathan Marquess, GPhA/AIP
Helen Sloat, Nelson Mullins
Emily Doppel, BrightSpring & McKesson
Naveed Tharwani, Gwinnett Drugs
Robert Brannon, Wellstar Health

Open Session

President Page established that a quorum was present and called the meeting to order at 9:02 a.m.

President Page greeted the members of the public who were present, and reminded everyone that the upcoming weekend was Mother's Day and he wished a great weekend to all the mothers in attendance.

Approval of Minutes

Mr. Stone made a motion to approve the Public and Executive Session minutes from the April 10, 2024, meeting. Vice President Cordle seconded, and the Board voted unanimously in favor of the motion.

Report of Licenses Issued

Mr. Stone made a motion to ratify the list of licenses issued. Vice President Cordle seconded, and the Board voted unanimously in favor of the motion.

Petitions for Rule Waiver or Variance

Rule Waiver Petition from Tracy's Medicine Center and Medicine Center of Atlanta: The Board discussed this request for a rule waiver. President Page stated that he believed the request to be for waiver of Rule 480-6-.01, to allow the petitioners to keep the same license number after a change in ownership. President Page noted that the Board had recently voted to amend this rule such that licensees could retain their license numbers in this situation. Mr. Azzolin observed that there was more than one rule related to a change in ownership, and that the petitioners had not specified from which rule they were requesting a

waiver. Mr. Azzolin continued, asking whether from an administrative standpoint the Board should specify each of those rules in granting a waiver. President Page, noted that he had also seen the petitioners' failure to specify a specific rule in their request, and requested clarification from Mr. Joiner. Mr. Joiner responded that the specific rule should be specified in the petition and advised that the Board should request supplement from the petitioners and bring the petition back in June. Mr. Azzolin asked whether the Board could approve the petition pending receipt of the petitioners' supplement, noting that this process would be a more practical approach. Mr. Joiner affirmed that this could be done.

There being no further discussion, Mr. Stone made a motion to grant the petition, pending receipt of a supplement from the petitioners specifying the rule from which they were requesting waiver. Mr. Bracewell seconded, and the Board voted in favor of the motion.

Rule Waiver Petition from Pathways Center for Behavioral and Developmental Growth: The Board discussed this request for a waiver from Rules 480-13-.01(i) and 480-13-.06(10). Mr. Stone requested clarification of the Board's understanding of this petition to be requesting to treat a separate building on the campus as a part of the hospital. President Page stated that he believed that to be the portion of their request relating to Rule 480-13-.01(i). President Page asked Director Troughton for the factual background based on GDNA observations. Director Troughton stated that this was a building across the parking lot and a non-public street from the hospital. He stated that the petitioners are essentially requesting to treat the separate building as a floor of the hospital for the purpose of being serviced by the hospital pharmacy. Director Troughton stated that he believed the petitioners had brought this petition to the Board because of a GDNA inspection. He continued, observing that the Board has in the past reviewed many similar requests to treat separate buildings on a hospital campus as floors of the hospital for the purpose of servicing those locations from the hospital pharmacy. Director Troughton stated that in the past, this Board and previous boards have not granted such requests. He further commented that there are a number of other methods by which the petitioners could get drugs from the hospital pharmacy to these areas and that the Board has previously discussed those methods in response to other petitions. He noted that this particular method has presented multiple other concerns in the past that the Board has found warranted denial of these requests. Director Troughton stated that during their inspection, GDNA advised the petitioners that they would need a waiver from the Board to proceed as they propose and that such requests have not been granted in the past.

At this point, Mr. Azzolin advised the Board that due to a potential conflict of interest, he was recusing himself from the decision on this petition.

Mr. Stone requested clarification from Director Troughton regarding how patients are currently being treated in the separate building. Director Troughton responded that this is an in-patient facility. He stated that the patients are in-patients but the building is located across the street from the hospital pharmacy and that the petitioners are requesting to provide services to those patients from the hospital pharmacy. He stated that the petitioners could get another pharmacist and pharmacy, and noted that the petitioners had identified that option in their petition citing it as a hardship. He further noted that this was not the only alternative available, and that the drugs could be provided to those patients by transferring control and custody of the drugs to the practitioner when they need to be moved across the street. Director Troughton reiterated that the way this has been looked at in the past by other boards and by the current board is that if they start granting these petitions they would be opening the door to a wide variety of situations wherein separate facilities are being treated as floors of the hospital. He stated that the concern is that these locations do not have a pharmacy, and are not in a situation where the pharmacist could quickly come upstairs to respond to a problem. Director Troughton concluded, stating that from an enforcement standpoint, every time a new

exception was allowed to the rule, it becomes harder for enforcement to keep up from an enforcement and investigative standpoint.

President Page asked if anyone from Pathways Center was present, but received no response from the audience. Director Troughton replied that GDNA Special Agent Eric Durham was present with him and that he was the agent who conducted the inspection of the petitioners hospital. Mr. Durham stated that the petitioners were treating the separate building “just like a med room in a hospital.” He stated that the petitioners were maintaining a Pyxis machine in the separate building, where the nurse would get all of the adolescent in-patients’ daily medications. He stated that they would get all of their drugs from that Pyxis machine. Mr. Stone asked whether, from a technology perspective, the storage of the drugs in a Pyxis machine in the separate building should have bearing on the Board’s decision, and whether the type of machine, Pyxis or RAMS should matter. Director Troughton responded that the technology was good, and reviewed the differences between a Pyxis and a RAMS system, and noted that the records with both systems were excellent. He clarified, that he did not think it was a matter of whether the technology is good, but rather the Board wants to expand the hospital in this manner given the pharmacy care and oversight, and diversion concerns.

Vice President Cordle stated that this petition, seemed to be very similar to a petition heard by the Board a few months ago which involved the use of a RAMS machine inside a jail. Mr. Azzolin stated that he also wanted to speak to previous petitions heard by the Board. Mr. Azzolin stated that the Board has gone through this scenario several times, and came to a clear conclusion in February 2023. At that time the Board identified 3 options for this situation. The first is that the provider receives the drugs and takes full responsibility of them, not a nurse but the provider. The second is that they open a second pharmacy in the separate building, either a retail pharmacy or a clinic pharmacy. Director Troughton then added that they could also open another hospital pharmacy. Mr. Azzolin then continued, stating that the third option is that the separate building location order their drugs directly, without going through the pharmacy, but that in this option the provider would have to receive the drugs and take responsibility for them. Mr. Azzolin observed that, the Board does not know whether there is a provider at the separate location signing off on and receiving those drugs. He stated that this was the scenario with the previous petition referenced by Vice President Cordle, the drugs being received by the jail in that petition were being received by a provider. In that case, the Board recommended that the petitioner come to the Board and explain their process. Director Troughton explained that a caveat to the situation described by Mr. Azzolin is that the provider does not necessarily have to sign for the drugs, they become responsible for the drugs.

Mr. Stone asked whether the Board should table this petition, and ask the petitioners to appear on the petition at a future meeting. Mr. Joiner advised that that option was available to the Board. Director Troughton added, that the important consideration for the Board was not whether the hospital could find a doctor to be responsible for the drugs as they likely could find one, but rather whether the Board wants to endorse a situation where drugs are being transported across an open, public, parking lot and street on a daily basis. Mr. Stone then asked whether the presence of the road separating the facilities was the chief concern. President Page then stated that he believed it was a more than that as there could be multiple locations on a hospital campus. Mr. Stone concluded that the Board would then find that where the separate location was not in the same building as the hospital pharmacy, the waiver should not be approved. Director Troughton explained that that conclusion is consistent with what the Board has done in the past. He added that the Board has approved some petitions which involved buildings that were adjacent, separated by a covered walkway, but that the distances between those structures was small.

Vice President Cordle stated that the Board has had this scenario come before it before, and it had addressed three potential solutions for the petitioners in those matters. He then asked whether the Board believed they needed to bring these petitioners in to advise them of those three solutions, or should they deny the petition and advise of those options in the denial letter. President Page stated that the latter option was the one he was leaning toward, and that the Board should vote on the matter.

There being no further discussion, Mr. Chang made a motion to deny the petition, with explanation of the board's previously articulated alternatives. Vice President Cordle seconded, and the Board voted unanimously in favor of the motion. Mr. Azzolin recused himself from the decision on this petition.

Rule Waiver Petition from Publix Supermarkets, Inc.: The Board discussed this request for a waiver of Rule 480-36-.01(4). President Page stated that the petitioners were seeking waiver of the restriction to a single secondary remote order entry pharmacist, and reminded the Board that this petition was similar to previous petitions from other chain pharmacies seeking the same waiver which the Board granted. He also explained that the Board has adopted an amendment to this rule which would allow for more than one secondary remote order entry pharmacist, and that this amendment is still moving through the rule making process. President Page concluded, stating that he did not see any issue with the petition and inquiring whether the Board had any questions or concerns.

There being no further discussion, Vice President Cordle made a motion to grant the petition. Mr. Stone seconded, and the Board voted unanimously in favor of the motion.

Rule Waiver Petition from Wesley Colston, Community Health Care Systems, Inc.: The Board discussed this request for a rule waiver. President Page stated that he did not see a specific rule stated on the petition, but his understanding was that this was a request for a waiver from Rule 480-10-.16(7)(a), regarding approval of a lockbox for access to a pharmacy. President Page asked Director Troughton for background on this petition from the GDNA site inspection.

Director Troughton stated that GDNA had been to the facility and that the location where the petitioners are proposing to place the lockbox is behind a locked door and is only accessible to the healthcare staff. He stated the location of the lockbox is not open to the public, which is consistent with the criteria the Board had set previously. He continued, saying that the facility has a separate alarm system for the pharmacy, and that from an enforcement perspective he did not see any reason to disallow use of this lockbox.

Mr. Azzolin asked whether the petitioners required a waiver in these circumstances, as his understanding was that only board approval of the lockbox was required prior to its use. Director Troughton agreed, affirming that he did not believe a waiver was required in this instance, but that it was the Board's decision as to whether a waiver was appropriate or not. Mr. Azzolin concluded, stating that if that was the case, then the appropriate response should be to deny the petition for a rule waiver, but to grant approval for the use of the lockbox pursuant to the rule. Mr. Joiner agreed, stating this was the appropriate measure.

There being no further discussion, Vice President Cordle made a motion to deny the petition for rule waiver, but to articulate approval for the use of the lockbox in the facility. Mr. Azzolin seconded, and the Board voted unanimously in favor of the motion.

Correspondences

Correspondence from Jordan Khail, Clinical Instructor, UGA College of Pharmacy: The Board viewed this correspondence for informational purposes only.

Correspondence from Robert Brennan, Wellstar West Georgia Medical Center: The Board discussed this correspondence seeking guidance on behalf of Wellstar West Georgia Medical Center (WWGMC), which currently holds a hospital pharmacy license. The correspondence requested guidance regarding whether the facility's hospital pharmacy license allows it to serve patients and maintain standard ward inventory in a commonly owned hospice located on the WWGMC campus. Mr. Robert Brennan was present and discussed the request with the Board. Mr. Brennan explained that he has been involved in the presentation of a number of similar petitions to the Board, and that in 2016 the Board voted to allow Trinity Hospital in Augusta to service the wound clinic that was located in a separate building on the hospital campus from the hospital pharmacy, and that no additional license was necessary in that matter. Mr. Brennan explained that this precedent was the "prism" through which they were viewing their operation and their waiver request. He further explained that there is a hospice on the WWGMC campus, in which the hospital pharmacy is maintaining an Omnicell system. During its last inspection, WWGMC was informed by GDNA that maintaining drugs in the Omnicell system as standard ward inventory may be in violation of the rules of the Georgia State Board of Pharmacy, and WWGMC was asked to appear before the Board to explain their operation. Mr. Brennan noted that WWGMC uses Omnicell systems in the maintenance of all of its standard ward inventory on its campus. Mr. Brennan articulated that it was WWGMC's position that "a fair and full reading of the hospital pharmacy regulations suggests that on-campus facilities should not have this restriction," as opposed to facilities located off-campus.

President Page thanked Mr. Brennan for his presentation, and asked Director Troughton for his thoughts from GDNA on whether this situation was different from the one previously discussed by the Board. Director Troughton stated that the board rules clearly say that a hospital pharmacy may service a hospice, but that in doing so the hospital pharmacy must comply with the rules in Chapter 480-24 relative to how to service a hospice. He explained that GDNA's point to WWGMC was that the rules allow a hospital pharmacy to service a hospice, but it must be done in the manner specified by the rules. He continued, stating that there is a line in the rules which states that a hospital pharmacy may not maintain floor stock in the serviced hospice. From GDNA's perspective, as the enforcement arm of the Board, WWGMC's proposed method of service was in violation of the board's rules. This was the reason GDNA suggested seeking guidance from the Board. Director Troughton reiterated that the concern was not whether the hospital pharmacy could service the hospice, but that the method being employed was not compliant with the rules. Director Troughton stated that their suggestion to WWGMC was to service the hospice with emergency kits as specified in the rules.

Mr. Azzolin stated that he believes there is some conflict in the rules between Chapters 480-13 and 480-24. Chapter 480-13 references 480-24 and says that according to 480-13-.01 the holder of a hospital pharmacy license is allowed to service patients of Nursing Homes, Long Term Care Facilities or Hospices as long as they are under the same ownership as the Hospital Pharmacy but also must be compliant with chapter 480-24. Furthermore, a Hospital Pharmacy is defined as that portion of a "Hospital facility" which 480-13-.01 defines as "as defined by the Department of Human Resources" (which correctively should state the Department of Community Health). However, 480-24-.04 states that all drugs supplied to the hospice must be obtained from a pharmacy having a retail pharmacy permit. He reiterated that this is a hospital pharmacy supplying the drugs. Director Troughton interjected, stating that the hospital pharmacy rules permit the hospital pharmacy to service the hospice. Mr. Azzolin continued, that he thinks the reason for this is that, as stated in Mr. Brennan's correspondence, the definition of the word "hospital" includes all areas that are licensed as the hospital and that the Hospice is located inside the walls of the building defined as a hospital. He stated that he believes the hospital pharmacy permit is applicable to all of those areas, and that the way the hospital pharmacy can distribute drugs to those areas is in compliance with the hospital pharmacy rules

without having to dispense under the retail rules. He concluded that the Board should review the hospital rules in Chapter 111 of the Rules and Regulations of the State of Georgia which are the Rules of the Chapter of Community Health, and the underlying law to determine whether or not the hospital pharmacy permit should reach all areas covered by the hospital license. He stated that if this was determined to be the case, this would open up the hospital pharmacy to allow service of all areas of the hospital campus which would include the use of dispensing cabinets such as the Omnicell cabinets used not only by WWGMC for Hospice patients, but also by other hospitals for areas such as Nursing Homes and Long Term Care Facilities under the same conditions. Mr. Stone agreed that the Board should research this issue to determine the appropriate scope of service for the hospital pharmacy. Director Troughton added that the way this has been enforced by GDNA is that a hospital pharmacy does not need a retail permit to service an on-campus hospice, but that in doing so the hospital pharmacy must comply with Chapter 480-24. He stated that the purpose of the rule was to require hospital pharmacies and retail pharmacies servicing hospice facilities to do so in the same manner. Mr. Azzolin stated that he believes the rules in Chapter 111 may lead to a different conclusion than has been reached in the past. He stated that while the position taken by the Board in the past has been consistent, that it has been void of the consideration of the rules in Chapter 111. He continued, stating that he believes now that this has been exposed, it presents an opportunity to re-evaluate the Board's position in light of those rules and possibly reach a different conclusion. Mr. Cotton added that he would be happy to do some legal research on this issue for the Board. Director Troughton added that if the Board reached a different conclusion, they would need to change some of their rules and how GDNA was enforcing them based on the new interpretation.

Mr. Azzolin asked the correspondents how they were currently operating. Mr. Don Davis, director of pharmacy for WWGMC responded, stating that they have 31 Omnicells within the campus, and that they have an Omnicell in a locked medication room which is badge-secured from the outside. They get push reports from the Omnicell multiple times per week and use a common health record between the hospital and the hospice. He added that when orders are generated for the hospice in-patients, they are verified by the hospital pharmacist and become medication orders on the hospice Omnicell machine. When the hospice nurses need to give a particular medication, they access the Omnicell and get the medication for that particular patient. The machine provides access to only the specific medication needed at that moment; other drugs stored in the machine are in separately locked drawers. The Omnicell maintains a perpetual inventory of the drugs in the machine. He stated that the pharmacy receives a count report from the machine daily, and a dispense-administration report which matches the record of dispensing to a drug order in Epic. They also get an override report showing the override administrations made. Additionally, drugs are delivered from the hospital pharmacy to the hospice by vehicle.

Mr. Azzolin thanked Mr. Davis for his explanation and asked that the Board allow the petitioners to continue to operate as Mr. Davis described while the Board researches this issue further.

Director Troughton stated that when GDNA encounters issues like this, their practice is to point out the issues, but unless there is an immediate danger to the public, they advise licensees not to change their practice until they have verified with legal counsel and the Board. He added that the technology being used is excellent and that the question is a matter of whether the means are compliant with board rules.

Mr. Stone proposed referring this matter to the Attorney General's office for legal advice.

There being no further discussion, Mr. Azzolin made a motion to refer this matter to the Attorney General's office for research and legal advice. Mr. Stone seconded, and the Board voted unanimously in favor of the motion.

Correspondence from Gwinnett Drugs: The Board discussed this correspondence seeking guidance on behalf of Gwinnett Drugs. The correspondence expressed concerns regarding the shipping of compounded drugs into Georgia by non-resident pharmacies which are located in states which may not enforce the requirements of the USP as strictly as Georgia. **Mr. Robert Brennan was present and discussed the request with the Board.** Mr. Stone stated that he agrees with the correspondents that this is a concern that should be investigated by the Board, as other states enforce the provisions of the USP differently. Mr. Azzolin stated that last month the Board asked for a referral for interpretation of the time-based limitation of the law as it relates to non-governmental entities. He continued stating that he agrees that Georgia's current application of the USP as it relates to compounding is likely more strict than what is being done in other states, and that there is likely to be a "happy balance" that he would like to see the Board have the autonomy to determine on its own without having to be subject only to USP provisions. He stated that he personally has a desire to make Georgia as business friendly to safely provide medications to patients as possible. He stated that he would be against further restricting out facilities in other states that are appropriately licensed just because they are in a state that has more favorable rules on the issue. Instead, what he would be in favor of is that this serve as a wake-up call for amending the law relative to USP to allow the Board of Pharmacy in Georgia to determine which aspects of USP should be enforced in the state of Georgia.

Mr. Cotton stated that relative to USP 800, he had received a letter from Mr. Bass with GPhA which will be on the agenda for the next Board meeting. He stated that this letter was addressed this issue and discussed what the Board's obligations under O.C.G.A. § 26-4-86 to enforce USP standards. Mr. Bass added, that his office had spent quite a lot of time developing this memo, and that the version with the Board was about 10 pages long, pared down from 20 or 29 pages originally. Mr. Bass stated that there was more there if the Board wanted to review it. President Page stated that what he was understanding from this discussion was that there was more for the Board to review for next month in determining the next step.

Mr. Naveed Tharwani from Gwinnett Drugs addressed the Board, stating that their concern in bringing this matter to the Board's attention was about safety. They are concerned that sterile compounded drugs from outside the state are being shipped into Georgia by pharmacies that are not adhering to the same USP standards as pharmacies located in Georgia are required to follow. Georgia pharmacies are forced to incur higher production costs in adhering to the USP guidelines as they are presently enforced.

Mr. Azzolin responded stating that he understood Mr. Tharwani to be saying that they have seen these drugs coming in to the state. He stated that what he knows of GDNA is that if we were seeing these drugs coming into Georgia and our agents had requested information from the pharmacy and were not receiving a response, that it would be brought to the Board for action against the Georgia pharmacy permit. He further articulated that non-resident pharmacies have to adhere to Georgia rules just like in-state pharmacies do. He said his assumption was that our agents would bring this to the Board's attention.

Mr. Tharwani added that with recent drug shortages, they are concerned that patients are more exposed and at risk than ever before.

Mr. Azzolin asked Director Troughton if GDNA agents had come across this issue. Director Troughton responded that he was not familiar with it, and he was not sure how Gwinnett Drugs would be aware of anything GDNA had requested from any licensee, and that this was not information that an agent would disclose. Mr. Tharwani explained that he had been in contact with some central fill pharmacies that had received requests from GDNA for records which they had to get from non-resident pharmacies, and which

had not been produced to the central fill pharmacies for them to produce to GDNA. Director Troughton stated again that he was not familiar with a situation like the one described and added that GDNA enforces USP 800 exactly as it is written because that is the charge to him from the Board and from the Governor. He stated that they attempt to enforce the law in a way that stops immediate public risks and works with pharmacies to achieve compliance. He affirmed that until such time as he receives direction from the Board or the Governor to the contrary, there will continue to be USP 800 inspections.

President Page thanked Mr. Bass for his memo, and rearticulated that from what he has heard there is more for the Board to consider and to discuss at its next meeting.

Georgia Drugs and Narcotics Agency – Mr. Dennis Troughton

Director Troughton introduced Special Agent Eric Durham to the Board. Director Troughton stated that Special Agent Durham currently covers eleven (11) counties, “just south of Rome all the way down to Columbus.” Director Troughton. Director Troughton stated Mr. Durham does a great job for GDNA.

Director Troughton reported that GDNA conducted 2,809 inspections and received 459 investigations for FY2024.

Attorney General’s Report – Mr. Justin Cotton

No report.

Executive Director’s Report – Mr. James Joiner

Continuing Education Report: Mr. Stone made a motion to ratify the below continuing education program approved since the previous meeting. Mr. Azzolin seconded, and the Board voted unanimously in favor of the motion.

Date of Program	Hours	Sponsoring Group	Program Title	CE Code
05/01/2024	0.5	The Medical Center – Atrium Navicent Health	Updated 2023 Beer’s Criteria	2024-0004
06/05/2024	0.5	The Medical Center – Atrium Navicent Health	Lemborexant (DAVVIGO) and its Role in Delirium	2024-0005

Miscellaneous: Mr. Joiner discussed the current short-staffing issues in the Board’s administrative office. He stated that since January 2024, the Board experienced vacancies in five out of its fifteen (15) positions, impacting every part of the Board’s organization. Mr. Joiner continued, saying that he mentioned this to say that the Board and administrative leadership are incredibly blessed to have the staff that they have. Every single member of the Board’s staff has had to pick up extra work and for most of the staff that has meant working nights and weekends just to keep the Board going. Mr. Joiner further explained that despite the shortage of personnel, the Board has not experienced a noticeable dip in productivity. He concluded by saying that he wanted to acknowledge the Board’s staff in public because they are a great staff and are working really hard at the moment to keep things moving, and that the Board is able to be where it is because of their efforts.

President Page added that he thinks Mr. Joiner has done a fantastic job since taking over as executive director and that he wanted to echo his comments that the staff has done a fantastic job as well.

Legal Services – Mr. James Joiner

Rule 480-22-.12 Amendments for HB557: Mr. Joiner stated that the Board had voted to post amendments to this rule during the public hearing in April, and that since that time HB557 had been signed including additional prescriptive authority for APRNs and PAs. Mr. Joiner suggested that the Board pull the rule back to make further amendments consistent with HB557 and then vote to post again at a later meeting.

President Page stated that he agreed, and that the Board should make all the changes at once instead of doing it bit-by-bit.

Mr. Stone made a motion and Mr. Cordle seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h) and § 43-1-2(h) to deliberate and to receive information on applications, investigative reports, and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Michael Azzolin, Jim Bracewell, Young Chang, Cecil Cordle, Chuck Page, and Dean Stone.

Executive Session

Georgia Drugs and Narcotics Agency

No report.

Cognizant's Report – Mr. Cecil Cordle

- GDNA Case #A35272
- GDNA Case #B35163
- GDNA Case #B35020
- GDNA Case #A35220
- GDNA Case #A35228
- GDNA Case #A35253
- GDNA Case #A35258
- GDNA Case #B35208
- GDNA Case #B35268
- GDNA Case #B35153
- GDNA Case #B35165
- GDNA Case #B35262
- GDNA Case #B35207

Attorney General's Report – Mr. Justin Cotton

Mr. Cotton presented the following consent orders for acceptance:

- M.M.S.
- C.H.P.
- L.F.
- Q.A.S.
- W.P.C.G.
- A.C.P.
- R.P.P.
- S.M.

Mr. Cotton discussed the following:

- U.S.P.

Executive Director’s Report – Mr. James Joiner

- W.R.S.
- A.P.
- R.H.A.

Legal Services – Mr. James Joiner

No report.

Applications

- B.K.Y.
- G.L.
- J.M.
- J.A.
- J.L.
- J.M.
- Z.W.
- A.P.
- J.H.
- S.O.
- J.S.
- J.S.
- J.V.
- K.C.
- M.I.
- N.L.
- R.T.

Correspondences/Requests

- A.P.
- M.S.
- P.I.
- I.C.
- W.P.N.
- M.R.B.
- O.P.
- B.H.
- B.H.
- D.P.
- G.B.
- M.A.

No votes were taken in Executive Session. President Page declared the meeting back in Open Session.

Open Session

Mr. Bracewell made a motion for the Board to take the following actions:

Cognizant’s Report – Mr. Cecil Cordle

- GDNA Case #A35272 Accept Private Interim Consent Order
- GDNA Case #B35163 Refer to the Department of Law
- GDNA Case #B35020 Close with Letter of Concern
- GDNA Case #A35220 Refer to the Department of Law
- GDNA Case #A35228 Change license status to Null and Void
- GDNA Case #A35253 Refer to the Department of Law
- GDNA Case #A35258 Refer to the Department of Law
- GDNA Case #B35208 Close with no action
- GDNA Case #B35268 Close with no action
- GDNA Case #B35153 Close with no action
- GDNA Case #B35165 Close with no action
- GDNA Case #B35262 Close with no action
- GDNA Case #B35207 Close with no action

Attorney General’s Report – Mr. Justin Cotton

Mr. Cotton presented the following consent orders for acceptance:

- M.M.S. Accept Public Consent Order
- C.H.P. Deny Consent Order counterproposal
- L.F. Accept Public Consent Order
- Q.A.S. Accept Public Consent Order
- W.P.C.G. Deny Consent Order counterproposal
- A.C.P. Deny Consent Order counterproposal
- R.P.P. Deny Consent Order counterproposal
- S.M. Deny Consent Order counterproposal

Mr. Cotton discussed the following:

- L.C.P. Table pending GDNA inspection
- U.S.P. Extend deadline for compliance

Executive Director’s Report – Mr. James Joiner

- W.R.S. Table for discussion at June meeting
- A.P. Table for discussion at June meeting
- R.H.A. Table for review and vote on ratification

Legal Services – Mr. James Joiner

No report.

Applications

- B.K.Y. Pharmacy Technician Approved
- G.L. Pharmacy Technician Approved
- J.M. Pharmacy Technician Approved
- J.A. Pharmacy Technician Approved
- J.L. Pharmacy Technician Denied

- J.M. Pharmacy Technician Denied
- Z.W. Pharmacy Technician Approved
- A.P. Pharmacist Approved
- J.H. Pharmacist Approved
- S.O. Pharmacist Approved
- J.S. DTM Approved
- J.S. DTM Approved
- J.V. DTM Approved
- K.C. DTM Approved
- M.I. DTM Approved
- N.L. DTM Tabled, pending receipt of signed protocol
- R.T. Nuclear Pharmacist Approved

Correspondences/Requests

- A.P. Notice of Discipline No action
- M.S. Notice of Discipline No action
- P.I. Notice of Discipline No action
- I.C. Notice of Discipline No action
- W.P.N. Notice of Discipline No action
- M.R.B. Notice of Discipline Referred to GDNA for investigation
- O.P. Notice of Discipline No action
- B.H. Request to extend intern license Approved
- B.H. Remote Order Entry Approved
- D.P. Request to extend intern license Approved
- G.B. Self-report No action, pending resolution of case
- M.A. Self-report Referred to GDNA for investigation

Vice-President Cordle seconded and the Board voted unanimously in favor of the motion.

There being no further business to discuss, the meeting was adjourned at 1:31 p.m.

The next scheduled meeting of the Georgia Board of Pharmacy will be held on Wednesday, June 5, 2024, at 9:00 a.m. at 2 MLK Jr., Drive, SE, 11th Floor, East Tower, Atlanta, GA 30334.

Minutes recorded by J. Clinton Joiner, II, Executive Director